Emetine Low Dose HCMV Replication Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for human cytomegalovirus (HCMV) infection are limited by side effects and the emergence of resistant viral mutants, necessitating the development of novel anti-HCMV compounds with different mechanisms of action.
Innovation Solution
Emetine, an old drug previously used to treat amebiasis, is discovered to inhibit HCMV replication at very low concentrations, interacting with ribosomal protein 14 and MDM2, and is shown to be effective in both in vitro and in vivo models, including mouse CMV inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HCMV drugs (viral DNA polymerase inhibitors) are used, then HCMV replication is inhibited, but side effects occur and resistant viral mutants emerge
Solution Approach 1:
The patent changes the mechanism of action parameter from viral DNA polymerase inhibition to ribosomal protein 14 interaction, fundamentally altering how the drug targets HCMV. This parameter change enables new therapeutic activity without the limitations of conventional polymetase inhibitors regarding side effects and resistance.
Solution Approach 2:
The patent introduces ribosomal protein 14 as an intermediary target between the drug and HCMV replication. By interacting with ribosomal protein 14 rather than directly inhibiting DNA polymerase, the drug achieves viral replication inhibition through a different cellular pathway, reducing direct toxicity to host cells.
2Reliability
If emetine is used at conventional doses for amebiasis, then amebiasis is treated, but the drug has narrow therapeutic window and potential toxicity
Solution Approach 1:
The patent changes the dose parameter from conventional amebiasis treatment doses to much lower concentrations (EC50 of 40 nM). This parameter change exploits the narrow therapeutic window by operating at doses where the drug is effective against HCMV but below toxic levels for host cells.
Solution Approach 2:
The patent achieves local quality differentiation by concentrating emetine activity at the viral replication level through specific interaction with ribosomal protein 14 in infected cells, while maintaining lower overall drug exposure in the host to minimize toxicity.
3Reliability
If emetine is administered at low doses for HCMV, then selectivity index increases, but dosing frequency and pharmacokinetic management become challenging
Solution Approach 1:
The patent leverages the long half-life of emetine (24 hours) to maintain continuous useful action against HCMV replication. This allows for extended dosing intervals (every 72 hours in mice), reducing the frequency of administration while maintaining therapeutic effect and selectivity.
Solution Approach 2:
The patent implements periodic action through dosing every 72 hours based on the drug's pharmacokinetic profile. This periodic administration schedule maintains effective tissue concentrations while allowing for drug clearance and reduction of cumulative toxicity, balancing selectivity with manageable pharmacokinetics.
Data Source
AI summary
The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.